8 weeks, single-center, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of Rubus coreanus extract on inhibition of platelet aggregation and blood coagulation

ee’s Biotech0 个研究点目标入组 80 人开始时间: 待定最近更新: 2019年3月11日

试验速览

暂无简介。

•1) male smoker aged not less then 20 years averagely consuming 10 cigarettes per day.
•2) not less then 70% of Platelet aggregation.
•3) People who sign the informed consent form before participating in the study

•1) subject with clinically significant myocardial infarction, angina pectoris,hemorrhagic lesion, cardiovascular disease under current medication or treatment
•2) subject who has taken aspirin, anticoagulant, antiplatelet agent within 2 weeks
•3)subject who has taken health functional food such as antioxidant(vitamin C, E), red ginseng , ginseng , chongkukjang, natto within 2 weeks
•4)subject under treatment for uncontrolled hypertension
•(over 160/100 mmHg)
•5)subject under treatment for uncontrolled diabetes (fasting plasma glucose 180mg/dl or diabetes patient starting drugs within 3 months)
•6)subject under treatment for thyroid disease etc. (However, subjects can be involved in the study based on doctor’s assessment)
•7)subject with operation medical history within 3 months
•8)subject whose creatinine level is twice higher than the normal range
•9)subject whose AST(GOT) or ALT(GPT) level is three times higher than normal range
•10)people complaining of a heartburn,dyspepsia, severe gut symptoms
•11)subject scheduled for participating in another study during this study period or who had participated in other study within 3 months
•12)subject who investigators think is not suitable for this study.

发起方

ee’s Biotech